Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × OTHER × Muscle-invasive Bladder Cancer × Clear all

Phase

Status

Recruiting 2 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 601 Neoplasms 391 Prostatic Neoplasms 337 Carcinoma, Non-Small-Cell Lung 321 Lung Neoplasms 262 Leukemia, Myeloid, Acute 256 Multiple Myeloma 230 Pancreatic Neoplasms 207 Neoplasm Metastasis 206 Leukemia 201 Colorectal Neoplasms 193 Lymphoma 179 Precursor Cell Lymphoblastic Leukemia-Lymphoma 177 Melanoma 177 Brain Neoplasms 165 Recurrence 150 Lymphoma, Non-Hodgkin 147 Leukemia, Lymphocytic, Chronic, B-Cell 144 Head and Neck Neoplasms 144 Myelodysplastic Syndromes 143 Ovarian Neoplasms 134 Carcinoma, Hepatocellular 127 Glioblastoma 126 Carcinoma, Renal Cell 112 Rectal Neoplasms 108 Lymphoma, Follicular 107 Lymphoma, Large B-Cell, Diffuse 104 Colonic Neoplasms 101 Hodgkin Disease 100 Glioma 93

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡